[PDF] Top 20 Projeto gráfico-editorial de uma revista customizada para um estúdio de tatuagem.

... arm Phase II ...eligible patients would indicate potential usefulness, while PFS of ...assessable patients were required with one-sided signi fi cance level of 5% and power of ...ineligible ... See full document

... multicenter trial, 519 patients with stages IA-IIIB lung cancer, of whom 61% had stage IA or IB disease, received either surgery alone or a combination of surgery with one of six ... See full document

... in patients with pre- viously treated advanced NSCLC in the pivotal trial ...that trial, erlotinib was associated with supe- rior survival in unselected patients ...of patients ... See full document

... strategies based on a better understanding of tumor biology are thus needed to maximize the effi- cacy of current ...to chemotherapy have been investigated, and the selection of effective chemo- therapy ... See full document

... 245 patients were enrolled into the gefitinib arm and 244 to ...1.21–3.78, P = ...for non-inferiority (upper CI limit for HR  ...proven non-inferiority, the similar survival and decreased ... See full document

... Pancreatic cancer is the fourth leading cause of cancer death in the US and is expected to become the second leading cause of cancer-related deaths in the next ...and gemcitabine/ ... See full document

... fluorouracil, gemcitabine) and FOLFIRINOX (folinic acid, 5FU, irinotecan, oxaliplatin), have been shown to give better results towards gemcitabine alone [11, ...comparing nab-paclitaxel ... See full document

... of non-small cell lung cancer (NSCLC) patients; however, limited data is available on advanced NSCLC patients of ...NSCLC patients of China, receiving ... See full document

... of patients leading a 50% decreased activity in erythrocytes; in ...these patients are at risk for severe toxicity, but they can tolerate a reduced ...of patients identifies those who are at risk and ... See full document

... correlation obtained between the CA 19-9 response and OS ( β = 0.365, p , 0.01). However, our findings are in line with those reported in the literature, with an OS of 8 months (95% CI: 7.13–8.86) and a PFS of 5 ... See full document

... 95. Latcha S, Jaimes EA, Patil S, et al. Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol. 2016;11:1173-1179. 96. Bestvina CM, Fleming GF. Chemotherapy for endometrial cancer in ... See full document

... the phase II portion, 240 patients with measurable metastatic triple-negative breast cancer and treatment naive for metastatic disease will be randomized 1:1:1 (stratified by disease-free ... See full document

... ZODIAC trial. With negative results of the ZEAL and ZEST trial presented at the annual ASCO conference last year, further evaluation of vandetanib as monotherapy or with pem- etrexed in unselected ... See full document

... summary, paclitaxel appears to modulate two key enzymes involved in the metabolism of cytidine ana- logues, including gemcitabine, and plays an integral role in the salvage of pyrimidine ...large ... See full document

... Twenty-four female BALB/c nude mice were purchased from SLC (Shizuoka, Japan). The research was approved by the Institutional Animal Care and Use Committee of Kobe University (Permit Numbers: P171201) and carried out ... See full document

... 124 patients underwent first-line chemotherapy, of whom, two patients, aged 71 and 78 years, discontinued the treatment because of a poor perfor- mance status caused by chemotherapy or ... See full document

... doublet chemotherapy, but those with proven EGFR mutations have superior outcomes with EGFR-TKI ...positive patients has been a paradigm shift in patient management improving response and PFS using ... See full document

... As previously mentioned, contributing factors to this immune-privileged TME include the paucity of T cell infiltration into the tumor, the low mutational burden in PDAC that produces few immunogenic ... See full document

... The primary endpoint was independently assessed ORR (complete and partial response) as per Response Evaluation Criteria in Solid Tumors v1.0. Secondary endpoints included progression-free survival (PFS; independent ... See full document

... advanced non-small cell lung cancer ...12,520 patients from 23 randomized controlled trials (RCTs) were enrolled to evaluate the efficacy and safety of VEGFR-TKIs quantitatively ... See full document